Delayed Prostate Cancer Therapy Suffern NY

The evidence seems to contradict the assumption that living with untreated prostate cancer is nerve-wracking for most patients, according to Dr. Roderick van den Bergh, of Erasmus Medical Center in Rotterdam, and colleagues.

Local Companies

Stanley J Oiseth
(914) 366-3902
701 N Broadway
Sleepy Hollow, NY
EDWARD GOLD, MD
(201) 666-3900
452 Old Hook Road
Emerson, NJ
SETH BENKEL, MD
(845) 634-2727
10 Esquire Road
New City, NY
JEFFREY AMBINDER, MD
(914) 245-6000
2649 Strang Boulevard
Yorktown Heights, NY
Oya Levendoglu Tugal, MD
914-493-7997
Irvington, NY
Andrew L Pecora
(201) 996-5900
20 Prospect Ave Suite 400
Hackensack, NJ
Norman Lester Rosen
(914) 965-2060
3333 Henry Hudson Way
Bronx, NY
SERGIO PIOMELLI, MD
(646) 256-4477
599 Overlook Place
Englewood, NJ
KAREN SEITER, MD
(914) 493-8375
19 Bradhurst Avenue
Hawthorne, NY
Edward Patrick Healey, MD
201-472-0884
58 Buttel Dr
Clifton, NJ
Data Provided by:
      

Provided By:

MONDAY, July 27 (HealthDay News) -- Men who delay treatment for their early prostate cancer are not especially anxious about living with the disease, new Dutch research shows.

The evidence seems to contradict the assumption that living with untreated prostate cancer is nerve-wracking for most patients, according to Dr. Roderick van den Bergh, of Erasmus Medical Center in Rotterdam, and colleagues. The findings are published in the Sept. 1 issue of Cancer.

The researchers surveyed 129 men regarding their levels of depression and anxiety over their treatment decision. More than 80 percent scored favorably low and compared well emotionally with patients who had opted for more aggressive treatment, the study found.

Men who were in poor general health and those with neurotic personalities expressed higher levels of anxiety and distress, suggesting that factors other than cancer may impact a patient's emotional response, the researchers noted.

The study is especially useful in an era when prostate-specific antigen tests and other screening exams are uncovering prostate cancer at increasingly earlier stages. Many physicians practice a "wait-and-see" approach to treatment, saving the more aggressive therapies for when the cancer grows or spreads, according to information in a news release from the American Cancer Society.

Nationally, prostate cancer is one of the most common cancers and is expected to strike more than 190,000 men this year, and result in over 27,000 deaths, according to the American Cancer Society. But thanks to more effective screenings and treatments, while one in six U.S. men will develop prostate cancer during their lifetime, only one in 35 will actually die of the disease. What's more, there are more than 2 million men in the United States who have been diagnosed with prostate cancer at some point and are still alive today, according to the society.

More information

The U.S. National Cancer Institute has more on prostate cancer.

SOURCE: American Cancer Society, news release, July 27, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Drug Combo Proves Powerful Against Lung Cancer Suffern NY
A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.
- Hormone Therapy for Lung Cancer Suffern NY
- Attack Of The Cancer Fighting Tomatoes Suffern NY
- Open Prostatectomy Versus Laparoscopic Procedure Suffern NY
- Hormone Therapy for Prostate Cancer Suffern NY
- Head and Neck Cancer Treatment Suffern NY
- Exercise for Prostate Cancer Suffern NY
- Diagnosis of Prostate Cancer Suffern NY
- Hormone Therapy for Breast Cancer Suffern NY
- Hormone Therapy for Early Prostate Cancer Suffern NY